Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis.

ABSTRACT:

Objective

To investigate the effect of teriflunomide on the efficacy and safety of seasonal influenza vaccine.

Methods

The 2011/2012 seasonal influenza vaccine (containing H1N1, H3N2, and B strains) was administered to patients with relapsing forms of multiple sclerosis (RMS) treated for ≥6 months with teriflunomide 7 mg (n = 41) or 14 mg (n = 41), or interferon-β-1 (IFN-β-1; n = 46). The primary endpoint was the proportion of patients with influenza strain-specific antibody titers ≥40, 28 days postvaccination.

Results

More than 90% of patients achieved postvaccination antibody titers ≥40 for H1N1 and B in all groups. For H3N2, titers ≥40 were achieved in ≥90% of patients in the 7 mg and IFN-β-1 groups, and in 77% of the 14-mg group, respectively. A high proportion of

SUBMITTER: Bar-Or A 

PROVIDER: S-EPMC3744268 | biostudies-literature | 2013 Aug

REPOSITORIES: biostudies-literature